The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
The French tried to reach Kaluga and swing through southern Russia, where they could find food and forage supplies. In the Battle of Maloyaroslavets, the replenished Russian army blocked the road to Kaluga. While an indecisive engagement, it nevertheless doomed the Grande Armée; with the Russians refusing to be dislodged, Napoleon was forced to retreat back down the Smolensk road along which he had already advanced, and which had already been denuded of supplies—most crucially, food. The French supply chain, already in tatters from the attrition of wagons and horses, began to collapse completely. The lack of horses also rendered Napoleon's cavalry ineffective, leaving the Grande Armée vulnerable to sustained guerrilla warfare by Russian peasants and irregular troops. The Grande Armée was dealt a further catastrophic blow by the onset of the Russian Winter, which the underfed and undersupplied Grande Armée was unprepared to cope with. When the remnants of Napoleon's army struggled across the Berezina River in November with the Russian army in pursuit, only 27,000 fit soldiers survived, with 380,000 men dead or missing and 100,000 captured. Napoleon then left his men and returned to Paris to prepare the defence against the advancing Russians. The campaign had effectively ended on 14 December 1812, when the last enemy troops left Russia. The Russians had lost around 210,000 men, but with their shorter supply lines, they soon replenished their armies. For every six soldiers of the Grande Armée that entered Russia, only one would make it out in fighting condition.
=== Cardiac morphogenesis === In the third week of fetal development the rudimentary heart (bilaterally symmetrical cardiac tube) undergoes a characteristic dextral looping, forming an asymmetrical structure with bulges that represent the incipient ventricular and atrial chambers of the heart. Arising from cells derived from the primary heart field in the cardiac crescent, HAND1 goes from being expressed on both sides of the heart tube to the ventral surface of the caudal heart segment and the aortic sac, then being restricted to the outer curvature of the left ventricle in the looped heart. In conjunction with HAND2 (a fellow bHLH transcription factor), complementary and overlapping expression patterns are thought to play a role in interpreting asymmetrical signals in the developing heart which leads to the characteristic looping. The two are implemented in cardiac development of embryos based on a crucial HAND gene dosage system. If HAND1 is over or under expressed then morphological abnormalities can form; most notable are cleft lips and palates. Expression was modeled with a knock-in of phosphorylation to turn on and off gene expression which induced the craniofacial abnormalities. HAND1 mutants also appear to develop a spectrum of cardiac abnormalities, as demonstrated in knock-out experimentation in the mouse model, where HAND1-null mice displayed defects in the ventral septum, malformation of the AV valve, hypoplastic ventricles, and outflow tract abnormalities.
So it was proposed that succinyl amino acid derivative should be an ACE inhibitor and succinyl-L-proline was found to be such an inhibitor. It was also known that the nature of penultimate amino acid residue of a peptide substrate for ACE influences binding to the enzyme. The acyl group of the carboxyalkanoyl amino acid binds the zinc ion of the enzyme and occupies the same position at the active site of ACE as the penultimate. Therefore, the substituent of the acyl group might also influence binding to the enzyme. A 2-methyl substituent with D configuration was found to enhance the inhibitory potency by about 15 fold of succinyl-L-proline. Then the search for a better zinc-binding group started. Replacement of the succinyl carboxyl group by nitrogen-containing functionalities (amine, amide or guanidine) did not enhance inhibitory activity. However a potency breakthrough was achieved by the replacement of the carboxyl group with a sulfhydryl function (SH), a group with greater affinity for the enzyme bound zinc ion. This yielded a potent inhibitor that was 1000 times more potent than succinyl-L-proline. The optimal acyl chain length for mercaptoalkanoyl derivates of proline was found to be 3-mercaptopropanoyl-L-proline, 5 times greater than that of 2-mercaptoalkanoyl derivates and 50 times greater than that of 4-mercaptoalkanoyl derivates. So the D-3-mercapto-2-methylpropanoyl-L-proline or Captopril was the most potent inhibitor.
Sources: en.wikipedia.org
=== Approvals === Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on 6 March 2000. Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on 24 January 2002. Fensolvi was approved by the FDA for children with central precocious puberty on 4 May 2020.
=== Constant-current constant-voltage charging === Constant current constant voltage (CC/CV) is the standard method used to charge lithium-ion cells. During the constant current phase, the charger applies a constant current to the battery at a steadily increasing voltage. Once the maximum charging voltage is reached, the charger changes to the constant voltage phase, where the voltage is held steady and the current gradually decreases, until a minimum current threshold is reached. If the starting voltage of the cell is too low, a very low charging current is usually used until the voltage reaches a safe level. This is sometimes referred to as trickle charging. When charging lithium-ion batteries made of multiple cells in series, top-balancing is also often performed.
==== Remote backup service ==== Remote backup services or cloud backups involve service providers storing data offsite. This has been used to protect against events such as fires, floods, or earthquakes which could destroy locally stored backups. Cloud-based backup (through services like or similar to Google Drive, and Microsoft OneDrive) provides a layer of data protection. However, the users must trust the provider to maintain the privacy and integrity of their data, with confidentiality enhanced by the use of encryption. Because speed and availability are limited by a user's online connection, users with large amounts of data may need to use seed loading and bulk restore.
At this stage another galectin, galectin-3, interacts with TRIM16 to guide selective autophagy of damaged lysosomes. TRIM16 gathers ULK1 and principal components (Beclin 1 and ATG16L1) of other complexes (Beclin 1-VPS34-ATG14 and ATG16L1-ATG5-ATG12) initiating autophagy, many of them being under negative control of mTOR directly such as the ULK1-ATG13 complex, or indirectly, such as components of the class III PI3K (Beclin 1, ATG14 and VPS34) since they depend on activating phosphorylations by ULK1 when it is not inhibited by mTOR. These autophagy-driving components physically and functionally link up with each other integrating all processes necessary for autophagosomal formation: (i) the ULK1-ATG13-FIP200/RB1CC1 complex associates with the LC3B/GABARAP conjugation machinery through direct interactions between FIP200/RB1CC1 and ATG16L1, (ii) ULK1-ATG13-FIP200/RB1CC1 complex associates with the Beclin 1-VPS34-ATG14 via direct interactions between ATG13's HORMA domain and ATG14, (iii) ATG16L1 interacts with WIPI2, which binds to PI3P, the enzymatic product of the class III PI3K Beclin 1-VPS34-ATG14. Thus, mTOR inactivation, initiated through GALTOR upon lysosomal damage, plus a simultaneous activation via galectin-9 (which also recognizes lysosomal membrane breach) of AMPK that directly phosphorylates and activates key components (ULK1, Beclin 1) of the autophagy systems listed above and further inactivates mTORC1, allows for strong autophagy induction and autophagic removal of damaged lysosomes.
Sources: en.wikipedia.org
Kodevirions are FSL modified viruses. Several FSL Kode constructs have been used to label viruses to assist in their flow-cytometric visualisation and to track them real time distribution in animal models. They have also been used to modify the surface of viruses with the intention of targeting them to be used to attach tumors (oncolytic).
Bolsonaro's response to the COVID-19 pandemic in Brazil received significant criticism after he sought to downplay the pandemic and its effects, opposed quarantine measures, and dismissed two health ministers, while the death toll increased rapidly. A polarizing politician, Bolsonaro has drawn both praise and criticism in Brazil for his views and comments, which have been described as far-right and populist. He is a vocal opponent of same-sex marriage, abortion, affirmative action, drug decriminalization, and state secularism. In foreign policy, he has advocated closer relations with Israel and with the United States; later in his presidency, he also made efforts to improve relations with the BRICS countries. In the 2022 general election Bolsonaro lost to Luiz Inácio Lula da Silva. On 8 January 2023, a mob of Bolsonaro's supporters stormed federal government buildings, calling for a coup d'état. On 30 June, the Superior Electoral Court blocked Bolsonaro from seeking office until 2030 for attempting to undermine the validity of the election through his unfounded claims of voter fraud, and for abusing his power by using government communication channels to both promote his campaign and to allege fraud. Testimony from military officials showed that Bolsonaro had planned a self-coup with the military to keep himself in power. In November 2024, he was indicted by the Federal Police of Brazil on multiple counts related to the planned coup. He was charged in February 2025, and the Supreme Court ruled he must stand trial.
Natural calcium is a mixture of five stable isotopes—40Ca, 42Ca, 43Ca, 44Ca, and 46Ca—and 48Ca, whose half-life of 4.3 × 1019 years is so long that it can be considered stable for all practical purposes. Calcium is the first (lightest) element to have six naturally occurring isotopes. By far the most common isotope is 40Ca, which makes up 96.941% of natural calcium. It is produced in the silicon-burning process from fusion of alpha particles and is the heaviest stable nuclide with equal proton and neutron numbers; its occurrence is also supplemented slowly by the decay of primordial 40K. Adding another alpha particle leads to unstable 44Ti, which decays via two successive electron captures to stable 44Ca; this makes up 2.806% of natural calcium and is the second-most common isotope. The other four natural isotopes, 42, 43, 46, 48Ca, are significantly rarer, each comprising less than 1% of natural calcium. The four lighter isotopes are mainly products of oxygen-burning and silicon-burning, leaving the two heavier ones to be produced via neutron capture. 46Ca is mostly produced in a "hot" s-process, as its formation requires a rather high neutron flux to allow short-lived 45Ca to capture a neutron. 48Ca is produced by electron capture in the r-process in type Ia supernovae, where high neutron excess and low enough entropy ensures its survival. 46Ca and 48Ca are the first "classically stable" nuclides with a 6-neutron or 8-neutron excess respectively.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.